Alzheimer's disease

Psychosis: The Other Big Alzheimer’s Therapeutic Target
BioSpace
Tue, 04/2/24 - 11:46 am
Alzheimer's disease
Alzheimer's disease psychosis
Cerevel Therapeutics
Karuna Therapeutics
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s
BioSpace
Mon, 04/1/24 - 12:14 pm
Biogen
Eisai
Alzheimer's disease
Leqembi
Aduhelm and an expensive failure to launch
Pharmaphorum
Tue, 03/26/24 - 04:25 pm
Biogen
Alzheimer's disease
Aduhelm
drug launches
Eisai and Biogen facing delay to Leqembi in Europe
Pharmaphorum
Mon, 03/25/24 - 11:22 am
Eisai
Biogen
Leqembi
Europe
Alzheimer's disease
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Roche Plots Neuro Comeback with Promising Mid-Stage Alzheimer’s Data
BioSpace
Tue, 03/12/24 - 11:14 am
Roche
Alzheimer's disease
monoclonal antibodies
Setbacks reset views on highly touted Alzheimer's and ALS drugs
Axios
Mon, 03/11/24 - 05:06 pm
Alzheimer's disease
ALS
Amylyx
Relyvrio
Eli Lilly
donanemab
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
BioSpace
Fri, 03/8/24 - 11:55 am
Eli Lilly
FDA
Alzheimer's disease
donanemab
Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline
Fierce Biotech
Thu, 03/7/24 - 11:38 am
Biogen
Alzheimer's disease
anti-tau antibodies
anti-inflammatory
Eisai
Leqembi
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected
Reuters
Thu, 03/7/24 - 11:07 am
Eisai
Leqembi
drug launches
Alzheimer's disease
Where’s Lilly’s Alzheimer’s approval?
Stat
Tue, 03/5/24 - 11:08 am
Eli Lilly
donanemab
Alzheimer's disease
Vivoryon ‘profoundly disappointed’ by phase 2 Alzheimer’s fail as stock crashes
Fierce Biotech
Mon, 03/4/24 - 11:11 am
Vivoryon
clinical trials
Alzheimer's disease
varoglutamstat
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
Eli Lilly Has More Than an Ozempic Competitor -- Much More
Motley Fool
Wed, 02/21/24 - 11:14 am
Eli Lilly
obesity
cancer
diabetes
psoriasis
Alzheimer's disease
Biogen has a fuzzy line of sight on prized Alzheimer’s drug
BioPharma Dive
Tue, 02/13/24 - 11:16 pm
Biogen
Alzheimer's disease
Leqembi
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
BioSpace
Thu, 02/8/24 - 10:57 am
Cassava Sciences
Alzheimer's disease
clinical trials
simufilam
Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi
Fierce Pharma
Wed, 02/7/24 - 11:33 am
Eisai
Biogen
FDA
Medicare
Leqembi
Alzheimer's disease
Biogen abandons Aduhelm efforts, focuses on Eisai-partnered Leqembi and pipeline drugs
Fierce Pharma
Wed, 01/31/24 - 11:50 am
Biogen
Aduhelm
Leqembi
Alzheimer's disease
FDA lifts clinical hold on INmune Bio’s Phase II Alzheimer’s trial
Clinical Trials Arena
Tue, 01/30/24 - 09:19 pm
INmune Bio
clinical trials
Alzheimer's disease
Xpro
FDA
Silo Pharma’s ketamine-based drug for Alzheimer’s effective against dementia symptoms in mice
Fierce Biotech
Fri, 01/26/24 - 12:02 pm
Silo Pharma
ketamine
Alzheimer's disease
SPC-14

Pages